{filename}

Publications

Categories

Filter by Topics

ADCC Gene Alteration adolescents ALK Angiogenesis Anti-TNF Alpha Therapy Apoptosis Asthma Autocrine Signaling Autoimmune Disorder B Cells benign Biofluid Biology of neoplasia Biomarker Analysis Biomarker Discovery Biomarker Validation Biomarkers Bladder Cancer Blood Brain Breast Cancer Breast milk Cancer Genomics Cardiovascular Disease CD3 CDKN2A mutation Cells Cerebrospinal Fluid Chemokines Childhood Atopic Dermatitis Chronic Obstructive Pulmonary Disease Circulating miRNAs cMET Colorectal cancer Comparative Study Comparison study computational toxicology Core Needle Biopsy COVID-19 Custom mRNA Cytokines Cytotoxic T Cells Dementia Developmental Immunotherapy Developmental Therapeutics Diabetes Differential Expression Differential Gene Expression Analysis DLBCL Drug Response Drug Safety Drug Targets Drug-induced Liver Injury Efficacy EGFR Muatations EMT Encephalophy epidemiology epigenomics Epstein-Barr ERBB3 Esophageal Cancer Exosomes extracellular miRNAs Extracellular Vesicles Fabry Disease Feasibility FFPE FGF Ligand Trap FGFR Fibrous Tumors Follicular lymphoma Gene Expression Gene Expression Profiling Gene Fusions Gene Signature Analysis Genetic Polymorphism Genitourinary cancer Glioblastoma Tumors Head and Neck Cancer Heart HER2 Histone Deacetylase Inhibitors HLA-E Homing HPV HTG EdgeSeq ALKPlus Assay EU HTG EdgeSeq Custom Assays HTG EdgeSeq DLBCL Cell of Origin Assay HTG EdgeSeq DLBCL Cell of Origin Assay EU HTG EdgeSeq DLBCL-COO-CE-IVD HTG EdgeSeq EGFR KRAS and BRAF Mutation Assay HTG EdgeSeq Immune Response Panel HTG EdgeSeq Immuno-Oncology Assay HTG EdgeSeq Immuno-Oncology Panel HTG EdgeSeq Lung Fusion Assay HTG EdgeSeq Lymphoma Panel HTG EdgeSeq miRNA Whole Transcriptome Assay HTG EdgeSeq miRNA Whole Transcriptome Panel HTG EdgeSeq Mouse mRNA Tumor Response Panel HTG EdgeSeq Oncology Biomarker Panel HTG EdgeSeq Path Assay HTG EdgeSeq PATH Assay HTG EdgeSeq Precision Immuno-Oncology Panel HTG EdgeSeq Precision Immunol-Oncology Panel HTG EdgeSeq System HTG EdgeSeq System Oncology Biomarker Panel HTG EdgSeq Immuno-Oncology Assay ibrutinib Immune Cells Immune Checkpoint Inhibitors Immune Related Genes Immune Response Immune System Immune Tolerance Immune-related Colitis Immuno-Oncology immunohistochemistry IHC Immunotherapy Inflammation Integrins Juvenile Arthritis Kidney Liposarcoma Liquid Biopsy Liver liver tissue Lung Lung cancer Lupus Lymph Node Metastasis Lymphocytes Lymphoma machine learning malignant Mechanism of Action Melanoma Mesothelioma MET Method Comparison Microenvironment MicroRNA miRNA Molecular Characterization Mouse mRNA custom mTOR pathway mTOR signaling multi-omics Multiple Myeloma Muscle Mutations MYC NAFLD Nash and Fibrosis Natural Killer Cells Neoantigens Neuroendocrine Tumor Neurologic non-Hodgkin Lymphoma Novel Therapeutic Targets NTRK1 Oesophageal Adenocarcinoma Oncology Oncology-Biomarker Oral Cancer Osteoarthritis Osteoclast Ovarian cancer Pancreas Paralysis Parkinson's Disease Pathogenesis Pathway analysis Pathway Analysis Patient Stratification PAXgene PBMCs PCA Cell Lines PD-1 PD-L1 PFAS PIK3CA mutation Placenta placenta Plasma Platform Comparison predictive biology Predictive Biomarkers Predictive Modeling Programmed cell death protein 1 Progression free-survival Prostate Prostate Cancer qNPA qPCR Radioimmunotherapy Rearrangements Renal Cell Carcinoma Renal Disease Reproductive Response rate RET Reveal Rheumatoid Arthritis Risk Score ROS1 safety Sarcoma Serum Signaling Inhibitors Signaling Pathways Signature Validation Signatures Sinonasal Carcinoma Skin SPECS Lung Consortium Squamous cell carcinoma Sub-typing surface plasmon Surveillance Survival Outcomes Survival plots Synovial Fluid synthetic miRNA T-Cell T-cells Technology Comparison Therapeutic Response Therapeutic targets Thymic Carcinoma Thyroid Cancer TMB Toxicity TP53 mutation Translational Medicine Transplantation Treatment Outcome Treatment Stratification Treatment Targets Tumor Biology Tumor Heterogeneity Tumor Immunobiology Tumor infiltrating lymphocytes Tumor Microenvironment tumor microenvironment Urine Urothelial carcinoma Uterus VEGFR Wound healing Xenograft Tissue

NGS-Based miRNA Profiling to Develop Signatures of Potential Clinical Applications

MicroRNAs — small, non-coding RNA molecules ranging from 18 to 25 nucleotides — have recently demonstrated potential as markers for diagnostic or prognostic applications due to their resilience to degradation, comprehensive annotation of more than 2,000 transcripts, and a deeper understanding of how miRNAs play a role in human disease. However, application of miRNA biomarkers has been limited by the difficulty of extracting quality product from clinically relevant sample types, the biases associated with preparing small, non-coding RNAs for next generation sequencing, and the data complexity caused by the sequencing of random fragments. 

In this online seminar, panelists will discuss two projects that are seeking to optimize miRNA profiling for eventual clinical applications. 

Speakers

Scott Tebbutt
Don Baldwin

Speaker Biographies

Scott Tebbutt, associate professor in the Department of Medicine at the University of British Columbia, will share his team's work developing tissue- and blood-based miRNA signatures of acute heart failure. Currently, there are no well-defined response biomarkers that can be used to monitor treatment or evaluate recovery in patients with severe inotrope-dependent acute heart failure. Dr. Tebbutt will present details from a study that is characterizing miRNAs as tissue and circulating biomarkers of heart failure in these patients over the first 30 days of medical management or mechanical circulatory support.  Scott Tebbutt is an associate professor in the Department of Medicine at the University of British Columbia. He is also chief scientific officer of the Prevention of Organ Failure (PROOF) Centre of Excellence — a not-for-profit organization dedicated to moving research findings into health care, and focused on non-invasive biomarkers that can diagnose and/or predict organ failure (heart, lung and kidney). His responsibilities include the evaluation of new, high-performance technologies to improve biomarker discovery, as well as computational biology approaches to better deal with cell type heterogeneity, and to allow integration of different omics data sets. Dr. Tebbutt holds a BA in biochemistry from the University of Oxford and a PhD in molecular genetics from the University of East Anglia (Cambridge Laboratory, John Innes Centre).

Don Baldwin, co-founder and chief scientific officer of MSK/dx, will discuss a project that is exploring miRNA profiling to identify biomarkers associated with bone fractures, with the goal of developing tests to help reduce the comorbidities and costs of treating complicated fracture cases. Dr. Baldwin will introduce a Latin square set of synthetic miRNAs developed by the Association of Biomolecular Resource Facilities that was used to demonstrate quantitative responses and specificity of the HTG EdgeSeq platform. The MSK/dx team then performed molecular profiling with the HTG EdgeSeq system to study circulating miRNAs in whole blood and serum from orthopedic trauma patients. 
 

Return To List